Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasGynecological OncologyNeuro-OncologyThoracic TumorsDiseaseAcute Lymphoblastic LeukaemiaBreast CancerGestational Trophoblastic NeoplasiaLung Carcinoma, Non-Small CellMalignant MeningitisNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, CNS-NHLPrimary Lymphoma of the CNSSubgroupEGFR activating mutationHER2+Leukemic MeningitisLymphomatous MeningitisICD10C34.-C50.-C79.3C83.-C83.3C83.7C85.9C91.0-D39.-D39.2MeSHBreast NeoplasmsBurkitt LymphomaGestational Trophoblastic DiseaseLymphoma, Large B-Cell, DiffuseMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceCISP20/ETOP100, GTN, Ind. (PID1608) -|- EMA/CO (ETOP100/DCTN0.5/MTRX1000/VNCR1.0/CYCL600) (PID1610) or (PID1607) with (PID1616)DA-EPOCH-R(R), Burkitt's lymphomaMTRX12, Malignant Meningitis, Ind. (PID608) -|- Cons. (PID871)PEME50/DEXA5, Malignant Meningitis, C1 (PID2529) -|- C2 (PID2530) -|- C3+ (PID2531)STUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DTRAS80, Malignant Meningitis, C1 (PID2526) -|- C2 (PID2527) -|- C3+ (PID2542)ChemotherapyChemo-substanceCytarabineDexamethasoneMethotrexatePemetrexedRituximabThiotepaTopotecanTrastuzumabChemo-substanceCytarabineDexamethasoneMethotrexatePemetrexedRituximabThiotepaTopotecanTrastuzumabChemo-substanceCytarabineDexamethasoneMethotrexatePemetrexedRituximabThiotepaTopotecanTrastuzumabChemo-substanceCytarabineDexamethasoneMethotrexatePemetrexedRituximabThiotepaTopotecanTrastuzumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDextrose 5%DimetindenFamotidineFolic acidFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDextrose 5%DimetindenFamotidineFolic acidFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDextrose 5%DimetindenFamotidineFolic acidFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDextrose 5%DimetindenFamotidineFolic acidFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateNo. Substances123912Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseConsolidationInductionMaintenanceTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 10g/dlArachnoiditisAstheniaDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHepatotoxicityLeukopeniaMucositisNauseaNeuropathyNeurotoxicityNeutropeniaPyrexiaSeizuresThrombocytopenia below 50 000/µlVisual DisturbancesVomiting only studiesPublicationAuthorAbramson JAlifrangis CFan CFerreri AJGlantz MGrossman SGroves MGökbuget NKopmar NKumthekar POberkampf FPfreundschuh MRausch CRoschewski MRubenstein JDiseaseaggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1Akute lymphatische Leukämie, B/T lymphoblastisches LymphomBurkitt-Lymphom, ZNS-Befall vor Beginn der Therapiediffus großzelliges Non-Hodgkin-Lymphom, HochrisikoHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieLeptomeningeale Metastasen beim Mamma-Ca, HER2+, ECOG 0-3Leptomeningeale Metastasen beim Mamma-Ca, HER2+, Karnofsky >50Lymphom mit positiver CSF Zytologie, Karnofsky > 50%Mengingeosis neoplastica durch solide Tumoren, Karnofsky > 50%Meningeosis neoplastica bei NSCLC, EGFR+, nach Vortherapie mit TKI, ECOG 1-3Meningeosis neoplastica bei soliden Tumoren 80% und hämatologischen Neoplasien 20%, ECOG 1-3Meningeosis neoplastica durch solide Tumoren, Karnofsky > 50%Refraktäre Meningeosis neoplastica, Erstlinie für Meningeosis neoplastica, Karnofsky > 60Trophoblastäre gestationale Neoplasie, high-risk (FIGO score 7 oder höher)Wiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50Zentrales B-NHL, Erstlinie, ECOG 0-3OriginCancer Center, Massachusetts General Hospital, BostonDepartment of Medicine, Brown University School of Medicine, Providence, Rhode IslandDepartment of Neurology at The Feinberg School of Medicine at Northwestern University, USDepartment of Oncology, Institut Curie-St Cloud, FranceDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasDSHNHL 2009-1, OPTIMAL > 60German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003Imperial College Academic Science National Health Service Trust, London, United KingdomIRCCS San Raffaele Scientific Institute, Milan, Italy, IELSG32 trialLymphoid Malignancies Branch, National Cancer Institute, BethesdaThe Johns Hopkins Oncology Center, Baltimore, MDThe Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of ChinaUniversity of Texas M. D. Anderson Cancer Center, Houston, TXProtocols in Revision 23 protocols foundProtocols under revision.Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602 V2.0)Cytarabine 50, intrathecal, maintenance, Malignant Meningitis (PID875 V1.0)Cytarabine 50, intrathecal, induction, Malignant Meningitis (PID873 V1.0)Cytarabine 50, intrathecal, consolidation, Malignant Meningitis (PID874 V1.0)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575 V1.0)Methotrexate 12, Malignant Meningitis, induction (PID608 V1.1)Methotrexate 12, Malignant Meningitis, consolidation (PID871 V1.1)Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231 V1.1)Methotrexate 12.5, Gestational Trophoblastic Neoplasia (PID1616 V1.1)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876 V1.1)Methotrexate 500/3000, Malignant Meningitis (PID1000 V1.0)Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001 V1.1)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 1 (PID2529 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 2 (PID2530 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 3+ (PID2531 V1.0)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133 V1.0)Thiotepa 10, Malignant Meningitis (PID867 V1.1)Topotecan 0.4, Malignant Meningitis (PID2520 V1.0)Trastuzumab 150, Malignant Meningitis (PID2523 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 1 (PID2526 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 2 (PID2527 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 3+ (PID2542 V1.0)
